28 Jun 2017

New development and licence agreement for a US inhaled generic (VR2081)

Chippenham, UK – 28 June 2017: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways products, today announces that through its subsidiary, Jagotec AG (collectively, “Vectura”, “the Group”), it has signed an exclusive development and licence agreement with Sandoz AG (“Sandoz”), a global leader in generic pharmaceuticals and a division of the Novartis Group, for the development of a generic of an existing major inhaled combination therapy for asthma and COPD in the US (VR2081) delivered using a pressurised metered dose inhaler (“pMDI”).

Read more


28 Jun 2017

Vectura hosts Capital Markets Event today in London today

Chippenham, UK – 28 June 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, is holding a Capital Markets Event for analysts and institutional investors today in London, starting at 13:00pm BST.

Read more


25 May 2017

Results of the Annual General Meeting held on 25 May 2017

Chippenham, UK, 25 May 2017: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll.

Read more


22 May 2017

Positive outcomes of the Phase I clinical study on VR942 presented today at the American Thoracic Society 113th annual conference

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways products, along with its co-development partner UCB (EBR: UCB) ("UCB"), announces they will present the positive outcomes of the Phase I clinical study (VR942-1-001) for their innovative inhaled biologic VR942 (UCB4144) at the American Thoracic Society 2017 International Conference (“ATS”) today, in Washington, D.C.

Read more


17 May 2017

Notice of Capital Markets Event

Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, will hold a Capital Markets Event in London for analysts and investors in the afternoon, Wednesday 28 June 2017.

Read more


11 May 2017

Update on the status of the ANDA for generic Advair Diskus®

Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading device and formulation business for inhaled airways products, announces that its partner on VR315 US (generic Advair Diskus® programme), Hikma Pharmaceuticals PLC ("Hikma") has confirmed it has received a Complete Response Letter ("CRL") from the US Food and Drug Administration ("FDA") in relation to its abbreviated new drug application ("ANDA") for its generic version of GlaxoSmithKline's Advair Diskus® (fluticasone propionate and salmeterol inhalation powder).

Read more


24 Apr 2017

Report and Accounts for the nine-month period ended 31 December 2016 and Annual General Meeting 2017

Vectura Group plc (LSE: VEC) ("Vectura", "the Company") announces that today it has released the following documents: Report and Accounts for the nine-month period ended 31 December 2016, Notice of Annual General Meeting 2017, Form of Proxy for the AGM

Read more


19 Apr 2017

External audit tender process successfully concluded

Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading device and formulation business for inhaled airways products, announces the successful conclusion of a tender process for the provision of its external audit starting from the 2017 financial year.

Read more


05 Apr 2017

First launch of a product incorporating Vectura’s FOX® smart nebuliser technology

Vectura Group plc's partner Bayer AG (“Bayer”) has launched Breelib™, the new nebuliser for Ventavis® (iloprost), in Poland.

Read more


03 Apr 2017

Launch of Utibron™ Neohaler® in the US

Chippenham, UK – 3 April 2017: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways products, confirms that Sunovion Pharmaceuticals Inc. (“Sunovion”), the US licensee of the Group’s partner Novartis AG (“Novartis”) has launched Utibron™ Neohaler® (indacaterol/glycopyrrolate) (“Utibron™”) in the US.

Read more


21 Mar 2017

Preliminary Results for the nine-month period ended 31 December 2016.

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”, “the Company”), an industry-leading device and formulation business for inhaled airways products, today announces its preliminary results for the nine-month period ended 31 December 2016.

Read more


08 Mar 2017

Company Act 2006 S430 (2B) Disclosure


06 Mar 2017

Board Change

Chippenham, UK - 6 March 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group", "the Company"), an industry-leading device and formulation business for inhaled airways disease, announces that Trevor Phillips, Vectura's Chief Operations Officer and President of US Operations ("COO"), will step down from the Board at the AGM on 25 May 2017 and leave the Company on 31 May 2017.

Read more


16 Feb 2017

Vectura achieves £9 million royalty cap from GSK Ellipta® products

Chippenham, UK, 16 February 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, announces that, based on the continued strong performance of GSK’s Ellipta® products reported by GSK in its Q4 2016 results announced on 8 February 2017 and the Group’s subsequent receipt of its royalty statement from GSK, it has achieved the £9 million calendar year royalty cap on net sales of these products in 2016, a year earlier than previously guided.

Read more


15 Feb 2017

Notice of Preliminary Results

Chippenham, UK, 15 February 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, plans to announce its Preliminary Results for the nine month period ended 31 December 2016 on Tuesday 21 March 2017.

Read more


25 Jan 2017

Seebri® / Ultibro® Breezhaler® 2016 sales reach $512 million triggering $5 million milestone receipt

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, announces that a sales milestone receipt of $5 million has been triggered following confirmation by Novartis that EU/ROW combined net sales of Seebri® Breezhaler® and Ultibro® Breezhaler® for the year to 31 December 2016 have reached $512 million.

Read more


24 Jan 2017

FDA approves initial IND to support Vectura’s wholly-owned programme VR647 in paediatric asthma

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, has received an Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to conduct a Phase 1 clinical trial with VR647.

Read more


12 Jan 2017

Audit Tender

Vectura announces that, as indicated in the Company's 2015 annual report and having completed the merger with Skyepharma PLC, it will shortly be undertaking a competitive tender process for the provision of its external audit starting from its 2017 financial year.

Read more


11 Jan 2017

Pre-close update

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading device and formulation business for inhaled airways disease, today announces an unaudited pre-close update ahead of its results for the nine months ended 31 December 2016, due in March.

Read more


10 Jan 2017

Vectura to present at the 35th Annual J.P. Morgan Healthcare Conference

Chippenham, UK – 10 January 2017: Vectura Group plc (LSE: VEC) (“Vectura”) an industry-leading device and formulation business for inhaled airways disease, today announced that James Ward-Lilley, Vectura's CEO, is scheduled to present an overview of the business at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, 11 January 2017, at 3:30pm PST (11:30pm GMT).

Read more


23 Dec 2016

Global development programme with Mundipharma for pMDI inhaled triple therapy (VR2076) for asthma and COPD

Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading device and formulation business for inhaled airways disease, today announces that it has signed a development and licence agreement with Mundipharma International Corporation Limited and a US independent associated company as the global development and commercialisation partner for the VR2076 (previously coded SKP-2076) pressurised Metered Dose Inhaler (“pMDI”) ICS/LABA/LAMA triple programme.

Read more


23 Dec 2016

Appointment of Joint Broker

Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, today announces the appointment of Numis Securities Ltd as the Company’s joint corporate broker alongside J.P. Morgan Cazenove, with immediate effect.

Read more


22 Dec 2016

VR876 – confirmation of alternative nebulised delivery device for Bayer’s Ventavis (iloprost) using adapted Vectura FOX® device

Chippenham, UK – 22 December 2016: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, announces that Bayer AG (“Bayer”), our partner on VR876, has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery (method of administration) for its currently marketed product Ventavis (iloprost) using Vectura’s handheld smart nebuliser FOX® device which Bayer has branded Breelib®.

Read more


21 Dec 2016

Licensing agreement signed for the launch of Utibron/Seebri in the US

Chippenham, UK – 21 December 2016: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, reports that Novartis announced today that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc., (MARLBOROUGH, Mass, “Sunovion”), for the US commercial rights to its three treatments for chronic obstructive pulmonary disease (“COPD”), Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Seebri™ Neohaler® (glycopyrrolate) inhalation powder, and Arcapta® Neohaler® (indacaterol) inhalation powder.

Read more


08 Dec 2016

Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment

Chippenham, UK – 8 December 2016: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, confirms the announcement by Novartis of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments, including steroid-containing combinations and long-acting bronchodilators, to the dual bronchodilator Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg.

Read more


23 Nov 2016

Interim results of the six months ended 30 September 2016


22 Nov 2016

Vectura announces a further collaboration with Hikma for the development of generic salmeterol for the US (VR730)

Chippenham, UK – 22 November 2016: Vectura Group plc (LSE: VEC) (“Vectura”, “the Group”), an industry-leading inhaled airways disease focused business, today announces that it has signed a US development and license agreement with Hikma Pharmaceuticals PLC (“Hikma”) (through its wholly-owned subsidiary, West-Ward Pharmaceuticals) for Vectura's VR730 product.

Read more


18 Oct 2016

Notice of Interim Results

Chippenham, UK, 12 October 2016: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, plans to announce its Interim Results for the period ending 30 September 2016 on Wednesday 23 November 2016.

Read more


07 Sep 2016

Results of the Annual General Meeting

Chippenham, UK, 7 September 2016: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll

Read more


07 Sep 2016

AGM trading update

Chippenham, UK – 7 September 2016: Vectura Group plc (LSE: VEC) ("Vectura", “the Group”), an industry-leading inhaled airways disease focused business, provides an update ahead of its Annual General Meeting (“AGM”) being held today at 12.00 noon at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH at which the Chairman, Bruno Angelici, will make the following statement to shareholders.

Read more


05 Sep 2016

New findings confirm Ultibro® Breezhaler® consistently more effective than Seretide® in reducing COPD flare-ups across different patient groups

Chippenham, UK – 5 September 2016: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, confirms the announcement by our alliance partner Novartis that new analyses from the head-to-head FLAME study confirmed that Ultibro® Breezhaler® is a more effective option for patients at risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide®, across different patient sub-groups1-10. These findings are being presented at the 2016 European Respiratory Society (ERS) International Congress this week in London, UK.

Read more


31 Aug 2016

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus® in persistence to treatment

New study shows that rate of patient persistence using Sandoz AirFluSal® Forspiro® is twice as high as for reference product Seretide® Diskus®

Read more


30 Aug 2016

Update on Mundipharma’s European Phase III trial of flutiform® in COPD and latest flutiform® in-market sales

Chippenham, UK – 30 August 2016: Vectura Group plc (LSE: VEC) ("Vectura", “the Group”), an industry-leading inhaled airways disease focused business, has been informed by its partner Mundipharma that its Phase III trial of flutiform® did not meet the primary endpoint of demonstrating statistically significant superiority in the reduction of annualised rates of moderate and severe COPD exacerbations when compared to mono-component LABA treatment alone.

Read more


05 Aug 2016

US$8 million Exparel® sales milestone from Pacira triggered

Vectura Group plc (LSE: VEC) ("Vectura", “the Group”), an industry-leading inhaled airways disease focused business, announces that a sales milestone receipt of US$8 million (circa £6.0 million) has been triggered following confirmation by Pacira Pharmaceuticals, Inc. (“Pacira”) that worldwide annual net sales of EXPAREL® (on a cash received basis) to 30 June 2016 were above US$250 million.

Read more


03 Aug 2016

Notice of AGM

Read more


27 Jul 2016

Vectura initiates legal proceedings against GSK relating to option-to-licence patent agreement and confirms 2016 revenue guidance

Vectura Group plc (LSE: VEC) ("Vectura", “the Group”), an industry-leading inhaled airways disease focused business, announces that it has received formal notification from GlaxoSmithKline (‘GSK’) that GSK does not wish to exercise the option to take a license to any additional patents under the patent licence and option agreement with Vectura dated 5th August 2010 for GSK’s Breo® Ellipta®/Relvar® Ellipta®, Anoro® Ellipta® and Incruse® Ellipta® products (the “Ellipta® products”).

Read more


22 Jul 2016

Change of accounting reference date

Vectura Group plc (LSE: VEC) ("Vectura", “the Group”), an industry-leading inhaled airways disease focused business, announces that the Board has approved a change in its accounting reference date from 31 March to 31 December, effective from the current financial year.

Read more


08 Jul 2016

Company Act 2006 S430 (2B) Disclosure

John Brown has stepped down from his position as a Non-Executive Director of Vectura Group plc (the "Company") with effect from 10 July 2016.

Read more


08 Jul 2016

Dr John Brown, Non-Executive Director, confirms date to step down

Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, confirms that as previously announced and as part of the now completed merger agreement with Skyepharma PLC, John Brown will step down from his role as a Non-Executive Director with effect from 10 July 2016.

Read more


05 Jul 2016

Board Committee changes post completion of merger with Skyepharma

Board amends: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, announces the following changes to the composition of its Board Committees.

Read more


30 Jun 2016

Licence Option Exercised

Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, announces that its partner, Ablynx nv ("Ablynx") is to exercise its commercial licence option on Vectura's smart nebuliser technology and progress its wholly-owned inhaled anti-RSV Nanobody®, ALX-0171, into a Phase IIb dose-ranging efficacy study.

Read more


10 Jun 2016

Latest news

May 29, 2015 at 11:23 AM

Company Act 2006 S430 (2B) Disclosure

Tags:

03 Jun 2016

Vectura reports successful completion of VR942 Phase I clinical study

Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in the development of products for the treatment of airways-related diseases, announces the successful completion of a Phase I clinical study (VR942-1-001) evaluating their innovative inhaled biologic immunomodulatory product ("VR942").

Read more


26 May 2016

Vectura Group plc – Preliminary Results for twelve months ending 31 March 2016

Chippenham, UK – 26 May 2016: Vectura Group plc (LSE: VEC) (“Vectura”), a leading independent inhaled device, formulation and development company focusing on the development of pharmaceutical therapies for airways diseases, today announces its preliminary results for the year ended 31 March 2016.

Read more


24 May 2016

Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”) and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura's proven dry powder inhaler (“DPI”) technology with Propeller's FDA-cleared digital health platform.

Read more


03 May 2016

Ablynx reports positive top line results Phase I-IIa study

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), announce the results of their partner, Ablynx, positive top line results from the first-in-infant Phase I/IIa study of its wholly-owned, inhaled, anti-RSV Nanobody, ALX-0171, in 53 infants, aged 1-24 months, hospitalised as a result of a respiratory syncytial virus (RSV) infection.

Read more


08 Apr 2016

VR315 US ANDA for Generic Advair Diskus® accepted for filing by FDA and milestone payment

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), confirms that our partner on VR315 US, Hikma Pharmaceuticals PLC (through its wholly-owned subsidiary, West-Ward Pharmaceuticals) has confirmed its abbreviated new drug application (ANDA) for fluticasone propionate and salmeterol inhalation powder has been accepted for filing by the U.S. Food and Drug Administration (FDA).

Read more


10 Feb 2016

VR315 US – Clinical Study Report final, triggers milestone payment

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), confirms that following the announcement in January 2016 confirming the completion of a clinical trial for VR315 in the US, the Clinical Study Report is now final. This triggers a cash milestone payment to Vectura of $2 million.

Read more


08 Jan 2016

VR315 US completes clinical study

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), announces the completion of a clinical trial for VR315 is the US. VR315 is a generic, inhaled combination therapy (fluticasone/salmeterol) for asthma/COPD delivered using Vectura’s proprietary dry powder inhaler and formulation technology.

Read more


18 Dec 2015

Ablynx’s anti-RSV Nanobody® completes enrolment of the first-in-infant Phase I/IIa safety study and extends the trial for younger infants using Vectura’s FOX® device

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), is delighted with the information released by Ablynx confirming that it has completed target enrolment of the first-in-infant Phase I/IIa safety study with its wholly-owned anti-RSV Nanobody, ALX-0171, and is on track to publish top line results in the first half of 2016.

Read more


09 Dec 2015

Commencement of first Phase III trial of inhaled triple therapy QVM149 for asthma and milestone payment

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”), confirms the commencement by Novartis of the first Phase III trial of QVM149, a new inhaled triple therapy for patients with moderate to severe asthma uncontrolled by standard ICS/LABA medication.

Read more


17 Nov 2015

FLAME study shows superiority of Novartis’ Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”), which specialises in the development of products for the treatment of airways-related diseases, confirms the information released today by Novartis announcing positive first results from the Phase III FLAME head-to-head trial examining the rate of chronic obstructive pulmonary disease (COPD) exacerbations.

Read more


17 Nov 2015

Vectura Group plc - Interim Results for the six months ended 30 September 2015

Vectura Group plc (LSE: VEC) (“Vectura”), which specialises in the development of products for the treatment of airways-related diseases, today announces its unaudited interim results for the six months ended 30 September 2015.

Read more


30 Oct 2015

US FDA approves new dual combination bronchodilator Utibron™ Neohaler® and stand-alone monotherapy Seebri™ Neohaler® for patients with chronic obstructive pulmonary disease

Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), which specialises in the development of products for the treatment of airways-related diseases, confirms the information released today by our alliance partner Novartis announcing that the US Food and Drug Administration (FDA) has approved the dual combination bronchodilator Utibron™ Neohaler® (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri™ Neohaler® (glycopyrrolate) – which is one component of Utibron™ Neohaler®.

Read more


30 Oct 2015

VR632 EU development milestone

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”), which specialises in the development of products for the treatment of airways-related diseases, announces that a cash milestone has been triggered by the successful achievement of a further development milestone associated with VR632 in the EU.

Read more


21 Oct 2015

Director declaration

Read more


17 Oct 2015

Notification of Interim Results

Vectura Group plc will be announcing its interim results for the six months ended 30 September 2005 on Wednesday, 16 November 2005.

Read more


02 Oct 2015

VR876 – Progress in Europe confirmed

Chippenham, UK – 2 October 2015: Vectura Group plc (LSE: VEC; “Vectura” or “the Company”), which specialises in the development of products for the treatment of airways-related diseases, announces that our undisclosed partner on the VR876 programme has achieved an important development milestone in Europe.

Read more


01 Oct 2015

VR315 US development milestone

Chippenham, UK – 1 October 2015: Vectura Group plc (LSE: VEC; “Vectura” or the “Company”), which specialises in the development of products for the treatment of airways-related diseases, announces that a further cash milestone has been triggered by the successful achievement of another development milestone associated with VR315 in the US.

Read more


24 Sep 2015

Results of General Meeting and Appointment of CEO

Chippenham, UK, 24 September 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at the General Meeting held today were duly passed on a poll

Read more


24 Sep 2015

Result of AGM

Chippenham, UK, 24 September 2015: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll.

Read more


02 Sep 2015

Notice of AGM

Read more


28 Jul 2015

Pre-IND meeting with the US FDA regarding VR647

Vectura announces successful pre-IND meeting with the US FDA regarding VR647

Read more


02 Jul 2015

Latest news

May 29, 2015 at 11:23 AM

Company Act 2006 S430(2B) Disclosure

Tags:

24 Jun 2015

Appoints James Ward-Lilley as CEO

Vectura Group plc, which specialises in the development of products for the treatment of airways-related diseases, announces the appointment of James Ward-Lilley as CEO and Executive Director.

Read more


18 Jun 2015

Planned development of QVM149 for asthma

Vectura Group plc confirms Novartis today announced plans to develop a new inhaled dry powder triple therapy for patients with moderate to severe asthma uncontrolled on standard ICS/LABA medication.

Read more


16 Jun 2015

Director declaration

In accordance with Listing Rule 9.6.14 Vectura Group plc announces that Neil Warner, Non-Executive Director of Vectura, has been appointed as Senior Independent Non-Executive Director of Trifast plc with immediate effect.

Read more


15 Jun 2015

Annual Report and Accounts 2015

In accordance with the Listing Rule 9.6.1, a copy of Vectura Group plc's Annual Report and Accounts 2015 has been submitted to the UK Listing Authority

Read more


04 Jun 2015

VR942 Phase I clinical study commences

Vectura Group plc announces that, following the successful completion of a number of pre-clinical studies, enrolment has commenced into a Phase I clinical study (VR942-1-001) in healthy volunteers and patients with asthma.

Read more


20 May 2015

Vectura Group plc – Preliminary Results for the year ended 31 March 2015

Vectura Group plc (LSE: VEC) announces its preliminary results for the year ended 31 March 2015.

Read more


14 Apr 2015

Gemünden - Planned Closure

Vectura Group plc announces its intention to close its site in Gemünden, Germany, effective by March 2016.

Read more


01 Apr 2015

Appointment of Non-Executive Director

Vectura Group plc (LSE: VEC), announces the appointment of Dr Per-Olof Andersson as a Non-Executive Director of the Board with immediate effect.

Read more


11 Mar 2015

AirFluSal launched in Portugal & Ireland

Vectura Group plc confirms that our partner Sandoz, has announced the launch of AirFluSal®Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

Read more


05 Mar 2015

NDA acceptance for QVA149 and NVA237

Vectura Group plc confirms that Novartis' New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) have been accepted for review by the US Food and Drug Administration.

Read more


03 Feb 2015

Chief Executive’s intention to step down

Vectura Group plc (LSE: VEC) announces today that after twelve years with Vectura, Dr Chris Blackwell, Chief Executive, has informed the Board of his intention to step down as Chief Executive.

Read more


09 Jan 2015

Vectura to present at JP Morgan Conference

Vectura Group plc announces that it is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, 14 January 2014, at 4:30pm PST (12.30am 15 January GMT).

Read more


08 Jan 2015

US Submission for NVA237 and QVA149

Vectura Group plc, confirms the information released today by our partner Novartis announcing that the New Drug Applications (NDAs) for QVA149 and NVA237 for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) were submitted to the US Food and Drug Administration (FDA) by Novartis in Q4 2014.

Read more


06 Jan 2015

Development and licence agreement with Janssen

Vectura Group plc today announced that the company has entered into a global development and licence agreement with Janssen Biotech, Inc. for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD.

Read more


06 Jan 2015

Vectura signs global development and licence agreement with Janssen in asthma/COPD

Vectura Group plc today announced that the company has entered into a global development and licence agreement with Janssen Biotech, Inc. (“Janssen”) for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD.

Read more


18 Nov 2014

Vectura Group plc - Interim Results for the six months ended 30 September 2014

Vectura Group plc announces its unaudited interim results for the six months ended 30 September 2014.

Read more


19 Aug 2014

Vectura Group plc - Interim Management Statement

Vectura Group plc publishes its Interim Management Statement for the period 1 April 2014 to 19 August 2014.

Read more


30 Jun 2014

Vectura announces a further US collaboration agreement with a leading international pharmaceutical company for the VR506 asthma therapy

Vectura Group plc announces that it has signed a US collaboration, development and license agreement for VR506, Vectura's clinical stage asthma monotherapy delivered using Vectura's proprietary technology.

Read more


24 Jun 2014

VR315 US development milestone

Vectura Group plc announces that it has triggered a milestone of $1.5 million associated with the development of VR315 in the US.

Read more


21 May 2014

Positive results for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)

Vectura Group plc confirms the information released today by Novartis announcing new data from the QUANTIFY study.

Read more


21 May 2014

Vectura Group plc – Preliminary Results for the year ended 31 March 2014

Vectura Group plc announces today its preliminary results for the year ended 31 March 2014.

Read more


01 Apr 2014

The smart nebuliser FOX wins Red Dot Design Award

Vectura Group plc announces that the smart nebuliser device FOX has won the 2014 Red Dot Award for product design.

Read more


13 Mar 2014

Acquisition of Activaero

Vectura Group plc announces the acquisition of Activaero GmbH for a total consideration of €130 million (£108 million) to be funded through a combination of existing cash and equity.

Read more


28 Feb 2014

South Korean Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has received South Korean marketing authorisation for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease, making it the first approval in Asia.

Read more


12 Feb 2014

Belgian Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has received Belgian marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


10 Feb 2014

Norwegian Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has received Norwegian marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


14 Jan 2014

Swedish Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has today received Swedish marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


13 Jan 2014

German Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has today received German marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


09 Jan 2014

Vectura to Present at the 32nd Annual J.P. Morgan Healthcare Conference, San Francisco

Vectura Group plc announced today that Dr Chris Blackwell, Vectura's Chief Executive Officer, is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, 15 January 2014, at 8:00 am PST (4:00 pm GMT).

Read more


18 Dec 2013

Update - Danish Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has today received Danish marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


18 Dec 2013

Danish Regulatory Authority confirm approval of AirFluSal® Forspiro®

Vectura Group plc confirms that our partner, Sandoz, has today received Danish marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), a new advanced inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

Read more


19 Nov 2013

Vectura Group plc - Interim Results for the six months ended 30 September 2013

Vectura Group plc which specialises in developing products for the treatment of airway-related diseases, today announces its unaudited interim results for the six months ended 30 September 2013.

Read more


14 Nov 2013

Bruno Angelici joins the Board of Vectura

Vectura Group plc is delighted to announce the appointment of Bruno Angelici to the Board as an Independent Non-executive Director and Non-executive Chairman Designate.

Read more


30 Sep 2013

Vectura and UCB to collaborate and share expertise in severe inflammatory disease

Vectura Group plc and UCB today announced that they have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease.

Read more


23 Sep 2013

Ultibro Breezhaler (QVA149) approved in Europe

Ultibro® Breezhaler® (QVA149), a first-in-class once-daily dual bronchodilator approved for COPD patients in Europe

Read more


23 Sep 2013

Board Announcement - Jack Cashman to retire as Non-Executive Chairman

Vectura Group plc (LSE: VEC; "Vectura") announces that, after 12 years as Non-Executive Chairman, Jack Cashman has made known his intention to retire from the Board.

Read more


23 Sep 2013

Result of AGM

Vectura Group plc announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.

Read more


20 Sep 2013

Approval of once-daily dual bronchodilator Ultibro® Inhalation Capsules in Japan (QVA149) for the treatment of COPD

Vectura Group plc confirms that the Japanese Ministry of Health, Labour and Welfare approved Novartis' once-daily Ultibro® Inhalation Capsules delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease.

Read more


04 Sep 2013

Presentations at ERS

Vectura Group plc advises that the following presentations will be made at the European Respiratory Society (ERS) Annual Congress 2013, being held in Barcelona, Spain, 7-11 September 2013.

Read more


13 Aug 2013

Vectura Group plc - Interim Management Statement

Vectura Group plc today publishes its Interim Management Statement for the period 1 April 2013 to 13 August 2013.

Read more


26 Jul 2013

Ultibro® Breezhaler® gains positive CHMP opinion

Vectura Group plc is pleased to note the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®.

Read more


19 Jun 2013

Vectura to Present at J.P. Morgan European Healthcare Conference 24th June 2013

Chippenham, UK 19th June 2013: Vectura Group plc ("Vectura"; LSE: VEC), announced today that Dr Chris Blackwell, Vectura’s Chief Executive Officer, is scheduled to present an overview of the Company at the J.P. Morgan European Healthcare Conference in London, on Monday 24th June 2013 at 1.45pm BST.

Read more


04 Jun 2013

Vectura Group plc – Potential royalty and milestone payments on Fibrocaps™

Vectura Group plc announces that the Company could receive a £2m change of control payment as part of the potential acquisition announced today, by The Medicines Company of ProFibrix B.V..

Read more


29 May 2013

New study finds ADEPT® effective in reducing Adhesions following Gynecological Laparoscopic Surgery

New study finds ADEPT® effective in reducing Adhesions following Gynecological Laparoscopic Surgery

Read more


29 May 2013

Vectura Group plc - Date of announcement of interim results for the six months ended 30 September 2007

Vectura Group plc (LSE: VEC), the pulmonary product development company, will be announcing its results for the six months ended 30 September 2007 on Monday 26 November 2007.

Read more


29 May 2013

Jefferies 2013 Global Healthcare Conference

Vectura Group plc announced today that Dr Chris Blackwell, Vectura's Chief Executive Officer, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Thursday, 6th June 2013, at 08:00 EST.

Read more


21 May 2013

Board change

Vectura Group plc announces that, after 11 years as Chief Financial Officer (CFO), helping to list Vectura on the London Stock Exchange and contributing to the growth of the Company, Anne Hyland is stepping down from her Board position and as CFO and Company Secretary at the end of June.

Read more


21 May 2013

Vectura Group plc – Preliminary Results for the year ended 31 March 2013

Vectura Group plc which specialises in developing inhaled therapies, principally for the treatment of airway diseases, announces today its preliminary results for the year ended 31 March 2013.

Read more


21 May 2013

New data presented at the American Thoracic Society meeting highlights strength of once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

Vectura Group plc confirms the information released today by Novartis announcing that new data from the chronic obstructive pulmonary disease (COPD) portfolio were presented today at the American Thoracic Society (ATS) International Conference May 17-22, 2013 in Philadelphia, PA, USA.

Read more


13 May 2013

Vectura establishes strategic partnership (Kinnovata) for new respiratory business in China

Vectura Group plc announces that it has established Tianjin Kinnovata Pharmaceutical Company Limited in China with two partners; Tianjin KingYork Group Company Limited, a leading Chinese pharmaceutical company and specialist manufacturer of corticosteroid based products, and Zendex Bio Strategy Inc, a private equity investor based in Hong Kong.

Read more


09 May 2013

Notice of Results

Vectura Group plc which specialises in developing inhaled therapies, principally for the treatment of respiratory diseases, will be announcing its preliminary results for the year ended 31 March 2013 on Tuesday 21 May 2013.

Read more


07 May 2013

Director Declaration

In accordance with Listing Rule 9.6.14 (2) Vectura Group plc (LSE:VEC) announces that Anne Hyland, Chief Financial Officer and an executive Director of Vectura, has been appointed as a Non-Executive Director of Elementis plc with effect from 1 June, 2013.

Read more


25 Apr 2013

Appointment of Joint Broker

Vectura Group plc is pleased to announce that it has appointed with immediate effect J.P.Morgan Cazenove as its joint corporate broker alongside Peel Hunt.

Read more


20 Feb 2013

Vectura to Present at Citi 2013 Global Healthcare Conference

Vectura Group plc announced today that that Dr Chris Blackwell, Vectura’s Chief Executive Officer, is scheduled to present at the Citi 2013 Global Healthcare Conference on Monday, 25th February 2013, at 15:00 PST.

Read more


13 Feb 2013

Vectura Group plc - Interim Management Statement

Vectura Group plc today publishes its Interim Management Statement for the period 01 October 2012 to 13 February 2013.

Read more


07 Jan 2013

Vectura to present at the 31st Annual J.P. Morgan Healthcare Conference

Vectura Group plc announced today that Dr Chris Blackwell, Vectura’s Chief Executive Officer, is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013, at 08:30 a.m. PST.

Read more


20 Nov 2012

Vectura Group plc - Interim Results for the six months ended 30 September 2012

Vectura Group plc which specialises in developing inhaled therapies, principally for the treatment of respiratory diseases, today announces its unaudited interim results for the six months ended 30 September 2012.

Read more


26 Oct 2012

Date of announcement of Interim Results for six months ended 30 September 2012

Vectura Group plc will be announcing its results for the six months ended 30 September, 2012 on Tuesday 20 November 2012.

Read more


01 Oct 2012

The European Commission approves once-daily Seebri® Breezhaler® as maintenance COPD treatment in the European Union

Vectura Group plc confirms the information released today by Novartis announcing that the European Commission has approved Seebri® Breezhaler® 44 mcg delivered dose, as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

Read more


28 Sep 2012

Approval for once-daily Seebri® Inhalation Capsules as maintenance COPD treatment in Japan

Vectura Group plc confirms the information released today by Novartis announcing that the Japanese Ministry of Health, Labour and Welfare has approved Seebri® Inhalation Capsules 50 mcg administered through the Breezhaler® device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease (chronic bronchitis and emphysema).

Read more


25 Sep 2012

QVA149 is filed as a treatment for COPD in Europe

Vectura Group plc confirms the information released today by Novartis that QVA149, an investigational drug for chronic obstructive pulmonary disease has been filed by Novartis for marketing authorisation with the European Medicines Agency.

Read more


18 Sep 2012

Results of the Annual General Meeting held on 18 September 2012

Vectura Group plc announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed by shareholders.

Read more


03 Sep 2012

Data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149

Vectura Group plc highlights that further data from the once-daily chronic obstructive pulmonary disease clinical trial programs were presented today by Novartis at the European Respiratory Society (ERS) Congress.

Read more


30 Aug 2012

QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year

Vectura Group plc confirms the information released today by Novartis that results from the fifth QVA149 Phase III study, SPARK, met its primary endpoint of a reduced rate of moderate-to-severe COPD exacerbations compared to glycopyrronium bromide (Seebri® Breezhaler®).

Read more


30 Aug 2012

Multiple presentations of clinical data on NVA237 and QVA149 at the European Respiratory Society Annual Congress, Vienna, 1-5 Sept 2012

Vectura Group plc advises that the following presentations will be made at the European Respiratory Society annual congress being held in Vienna, Austria, 1-5 September 2012.

Read more


28 Aug 2012

Notice of AGM

Vectura Group plc today gives notice of AGM

Read more


15 Aug 2012

Vectura appoints Corporate Development Director

Vectura Group plc announces that Dr Karl Keegan, will join the Company as Director of Corporate Development on 3 September 2012.

Read more


15 Aug 2012

Vectura Group plc - Interim Management Statement & VR315 US development milestone

Vectura Group plc today publishes an Interim Management Statement for the period from 1 April 2012 to 15 August 2012, and announces that it has achieved a milestone relating to continued US development progress on its lead asthma/COPD generic programme VR315.

Read more


22 Jun 2012

Once-daily Seebri® Breezhaler® receives positive CHMP opinion to treat COPD patients in the EU

Vectura Group plc confirms the information released today by Novartis, that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri® Breezhaler®.

Read more


17 May 2012

NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients

Vectura Group plc confirms the information released today by Novartis that results from the pivotal Phase III GLOW2 study demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period.

Read more


03 May 2012

Vectura's Chief Operations Officer appointed to the Board

Vectura Group plc announces that Dr Trevor Phillips, BSc PhD MBA, will join the Board with effect from 1 June 2012.

Read more


26 Apr 2012

Vectura Group plc - Preliminary Results

Vectura Group plc which specialises in developing inhaled therapies, principally for the treatment of respiratory diseases, today announces its preliminary results for the year ended 31 March 2012.

Read more


24 Apr 2012

QVA149 ILLUMINATE Phase III COPD study meets primary endpoint and clarification of anticipated timing of US filings for NVA237 and QVA149

Vectura Group plc confirms the information released today by Novartis that a fourth study in the IGNITE programme has met its primary endpoint.

Read more


11 Apr 2012

Notice of Results

Vectura Group plc will be announcing its preliminary results for the year ended 31 March 2012 on Thursday 26 April 2012.

Read more


11 Jan 2012

Vectura Group plc – Interim Management Statement

Vectura Group plc today publishes its Interim Management Statement for the period 01 October 2011 to date.

Read more


back to top